KIKK Capital

River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing. Currently pharmaceutical companies spend a billion dollar figure on the development of a new drug entity, with a 90% chance of it failing to reach the market. The most common reason for failure during this developmental stage is drug induced cardiac toxicity. To solve this issue we develop 3D cardiac tissues, resembling the working human heart, for advanced drug discovery and toxicity screening using a multidisciplinary human stem cell-based approach.

Pepscope BV, a biotechnology company, develops protein kinase activity profiling technologies. The company offers QuantaKinome, a solution to the pharmaceutical industry and academic researchers to improve the discovery and development of novel kinase inhibitors and other therapeutic compounds to find new applications of existing compounds and in due course to select optimal therapies for individual patients. Pepscope BV was founded in 2012 and is based in Nijmegen, the Netherlands.

Toxys B.V., based in Leiden, the Netherlands, is a biotechnology company focused on in vitro toxicity screening solutions. The company specializes in identifying the hazardous and potential carcinogenic properties of novel compounds early in the product and drug development process. By providing essential information, Toxys enables its clients to make informed decisions about which compounds to advance in their development pipelines. This approach not only supports the creation of safer and more effective medicines and products but also aims to reduce the reliance on animal testing.